CEP
ALXN

Chicago Equity Partners’s Alexion Pharmaceuticals ALXN Stock Holding History

Chicago Equity Partners’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		$425K Sell
4,730
-30,075
-86% -$2.95M 0.04% 470
2019
Q4 		$3.76M Buy
34,805
+18,225
+110% +$1.95M 0.22% 122
2019
Q3 		$1.62M Buy
16,580
+14,360
+647% +$1.62M 0.08% 370
2019
Q2 		$291K Buy
2,220
+160
+8% +$20.6K 0.01% 808
2019
Q1 		$278K Sell
2,060
-7,530
-79% -$936K 0.01% 775
2018
Q4 		$934K Buy
+9,590
New +$1.13M 0.04% 500
2017
Q4 		– Sell
-2,280
Closed -$320K – 857
2017
Q3 		$320K Buy
+2,280
New +$310K 0.01% 679
2015
Q2 		– Sell
-2,865
Closed -$497K – 535
2015
Q1 		$497K Sell
2,865
-100
-3% -$18.1K 0.01% 346
2014
Q4 		$549K Sell
2,965
-765
-21% -$142K 0.01% 311
2014
Q3 		$618K Sell
3,730
-5,845
-61% -$960K 0.02% 308
2014
Q2 		$1.5M Sell
9,575
-52,260
-85% -$8.25M 0.04% 244
2014
Q1 		$9.41M Buy
61,835
+59,360
+2,398% +$9.44M 0.26% 120
2013
Q4 		$328K Sell
2,475
-4,925
-67% -$591K 0.01% 351
2013
Q3 		$859K Sell
7,400
-250
-3% -$27.4K 0.03% 305
2013
Q2 		$705K Buy
+7,650
New +$737K 0.02% 322

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Chicago Equity Partners's ALXN Position: Q1 2020 in Review

Chicago Equity Partners reduced its Alexion Pharmaceuticals (ALXN) stake by 86% in Q1 2020, selling an estimated $2.95M and leaving 4,730 shares worth $425K. The position accounts for 0.04% of the portfolio, ranked #470.

Chicago Equity Partners first reported a position in ALXN in Q2 2013 and has held it in 15 quarters since. The position peaked at $9.41M in Q1 2014. 654 funds tracked by Wall St. Rank hold ALXN as of Q1 2020.

  • Chicago Equity Partners held 4,730 shares of Alexion Pharmaceuticals worth $425K as of Q1 2020.
  • Chicago Equity Partners sold 30,075 Alexion Pharmaceuticals shares in Q1 2020, an estimated $2.95M.
  • Alexion Pharmaceuticals made up 0.04% of Chicago Equity Partners's portfolio in Q1 2020, its #470 holding.
  • Chicago Equity Partners first reported a position in Alexion Pharmaceuticals in Q2 2013 and has held it in 15 quarters since.
  • Chicago Equity Partners's Alexion Pharmaceuticals position peaked at $9.41M in Q1 2014.
  • 654 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2020.

Based on Chicago Equity Partners's 13F filing for Q1 2020, filed 6 May 2020.